A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants

Inclusion Criteria:

• Body mass index (BMI) is 18.0 to 32.0 kg/m^2.

• Must either be: postmenopausal, permanently surgically sterile, or perimenopausal orpremenopausal and practicing a method of birth control until at least 30 days afterthe last dose of study drug.

• Have CD19+ B-cell count > 150 cells/μL at screening.

Exclusion Criteria:

• History: of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic,cardiovascular, pulmonary, or hepatic diseases within the past 6 months that in theoption of the investigator would adversely affect her participating in this study.

• History of any clinically significant sensitivity or allergy to any medication orfood.

• History of or active medical condition(s) or surgical procedure(s) that might affectgastrointestinal motility, pH, or absorption [e.g., Crohn's disease, celiac disease,gastroparesis, short bowel syndrome, gastric surgery (except pyloromyotomy forpyloric stenosis during infancy), cholecystectomy, vagotomy, bowel resection, etc.].